Key Takeaways
- A BioFuture panel made up of pharmaceutical executives, a Democratic lawmaker and a health economist debated some of complicated issues industry is facing.
- Congressman Jake Auchincloss (D-Mass) said he is sympathetic to industry’s lobbying efforts to change parts of the IRA and seek PBM reform.
- Industry representatives said pharma also needs to take responsibility for high drug prices.
New policies on drug pricing implemented by the US government under the Inflation Reduction Act (IRA), the Federal Trade Commission (FTC)’s actions on M&A, and the thorny role of pharmacy...
An expert panel made up of pharmaceutical executives, a Democratic lawmaker and a health economist debated some of the complicated issues industry is navigating in the US – and even...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?